Download Files:
LtaS-IN-1
$150 – $950
Products Details
Product Description
– LtaS-IN-1 (compound 1771) is a potent small-molecule inhibitor of Lipoteichoic acid (LTA) synthesis in multidrug-resistant (MDR) E. faecium and by altering the cell wall morphology. LtaS-IN-1 alone inhibits Enterococcus.spp 28 strains with varying MIC values ranging from 0.5 μg/mL to 64 μg/mL. LtaS-IN-1 combination with antibiotics abolishs multidrug-resistant E. faecium growth almost completely[1].
Web ID
– HY-135813
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C24H17N3O5
References
– [1]Paganelli FL, et al. Lipoteichoic acid synthesis inhibition in combination with antibiotics abrogates growth of multidrug-resistant Enterococcus faecium.Int J Antimicrob Agents. 2017 Mar;49(3):355-363.
CAS Number
– 877950-01-1
Molecular Weight
– 427.41
Compound Purity
– 98.14
SMILES
– O=C(OCC(NC1=NN=C(C2=CC=CC=C2)O1)=O)CC3=COC4=CC=C5C=CC=CC5=C43
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– DMSO : 125 mg/mL (ultrasonic)
Target
– Bacterial
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
